# Oral Dosage Form New Animal Drugs; Lufenuron Tablets; Milbemycin Oxime and Lufenuron Tablets; Nitenpyram Tablets
> **Food and Drug Administration** · Final rule. · Published 2003-08-29 · Effective 2003-08-29 · 68 FR 51904
## Document
- **Document number:** 03-22072
- **Category:** other
- **Sub-agency:** Food and Drug Administration
- **Federal Register citation:** 68 FR 51904
- **CFR reference:** 21 CFR 520
- **Publication date:** 2003-08-29
- **Effective date:** 2003-08-29
## Abstract

The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of two original new animal drug applications (NADAs) and three supplemental NADAs filed by Novartis Animal Health US, Inc. The original NADAs provide for the concurrent oral use in dogs of approved milbemycin oxime and lufenuron flavor tablets with nitenpyram tablets to kill adult fleas and prevent flea eggs from hatching and for the concurrent oral use in dogs and cats of approved lufenuron flavor tablets with nitenpyram tablets to kill adult fleas and prevent flea eggs from hatching. The supplemental NADAs provide appropriate labeling for the concurrent uses of the individual products and, for lufenuron flavor tablets, use in puppies and kittens as young as 4 weeks of age.

## Source
- [Federal Register document](https://www.federalregister.gov/documents/2003/08/29/03-22072/oral-dosage-form-new-animal-drugs-lufenuron-tablets-milbemycin-oxime-and-lufenuron-tablets)
---
*AI Analytics · CC0 1.0*